SLC5A2 and type 2 diabetes mellitus: Studies assessing SGLT2 inhibitors reported a decreased risk of the primary composite endpoint of fatal and non-fatal myocardial infarction, stroke, or cardiovascular deaths compared to placebo when added to standard antihyperglycemic treatment in patients with type 2 diabetes [11-12].